Covidien campaign touts surgery for Type 2 diabetes

Share this article:
Covidien is launching an educational campaign aimed at raising awareness of gastric bypass surgery as an option to treat type 2 diabetes among morbidly obese sufferers.

The “Our Resolution” campaign includes events aimed at both physicians and patients, and features Stacey Halprin, an “actress, author and frequent Oprah guest” whose struggle with morbid obesity and diabetes was chronicled by The Oprah Winfrey Show. At her heaviest, Halprin weighed 560 and suffered from type 2 diabetes. She underwent the surgery and is now down to 190 and diabetes-free.

A study recently published in The American Journal of Medicine found that the surgery, for which Covidien makes a number of devices, resolves type 2 diabetes in 77% of cases.

Our Resolution kicks off on Sunday at the annual convention of the American Society for Metabolic & Bariatric Surgery, where the company will be launching a professional site,, which includes micro-sites for surgeons, primary care physicians, bariatric coordinators and nurses.  On the patient side, the company will have a presence at several American Diabetes Association Diabetes Expos, where it will offer workshops and direct patients to

"The medical and surgical communities are coming together to recognize that this surgery has a profound impact on type 2 diabetes in many cases," said Gene Stewart, global director for bariatric market development at Covidien. "We want to put that information in people's hands."

Morrissey & Co. is handling PR for the effort, and Rosetta is handling the digital assignment. The company plans to run journal ads and banner ads to drive traffic to the sites.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...